VaxGen plans to relist shares

South San Francisco biopharmaceutical firm VaxGen Inc. (Pink sheets: VXGN) said it is now current on its financial reporting obligations with the U.S. Security and Exchange Commission and plans to relist its common stock on a nationally recognized stock exchange.

VaxGen has suffered a series of setbacks.

The company, which suffered a well publicized failure of an AIDS vaccine it was developing in 2003, was delisted from the Nasdaq exchange in 2004 for failing to promptly file financial reports with federal authorities as required. It then lost a U.S. government contract to provide an anthrax vaccine in December 2006 after missing a key deadline.

businessBusiness & Real Estate

If you find our journalism valuable and relevant, please consider joining our Examiner membership program.
Find out more at www.sfexaminer.com/join/

Just Posted

Fishermen, port struggling to recover from Pier 45 fire

Loss to fishing industry alone could be in the millions

Texts show Mayor Breed ordering police chief to ‘clear’ out homeless

Newly released text messages are offering the public a behind-the-scenes glimpse of… Continue reading

‘Shared Spaces’ program will let restaurants, retail expand into outdoor spaces

City to grant permits for use of sidewalks, parking for business operations

Hair salons, barbershops can reopen now, in Stage 3 of Newsom’s plan

By Taryn Luna Los Angeles Times Gov. Gavin Newsom issued welcome news… Continue reading

State issues guidelines allowing places of worship to resume services

Local black ministers, civil rights leaders call for churches to remain closed

Most Read